|
|
|
|
|
|
|
|
(Australia) media
AN AUSTRALIAN medical expert says a different approach to treatment of
rare cancers is needed, with research showing rare cancers contribute to
30% of deaths from the disease while less than 20% of funding goes to
them.
University of South Australia's Professor Ian Olver said in the Medical
Journal of Australia, published Monday, that research showed more than
80% of cancer research funding went to blood cancers and five solid
cancers (breast, colorectal, prostate, melanoma and lung), while rare
cancers such as pancreatic, ovarian and brain received less funding.
Rare cancers are defined as having fewer than six cases per 100,000 head of population a year.
"If less research is being performed to provide data, and the low
incidence of rare cancers makes large randomised clinical trials
impractical, there are few evidence-based guidelines regarding rarer
cancers to which clinicians can refer," Prof Olver said.
He said ovarian cancer was a good example of how approaches to rare cancer treatment needed to evolve.
He said common cancers which had improved survival rates, including breast and bowel, had screenings for early detection.
But a population screening test would be difficult to achieve for ovarian cancer, he said.
"The heterogeneity of ovarian cancer suggests that a population
screening test based on a panel of biomarkers will be difficult to
achieve."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.